Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1447817
This article is part of the Research Topic PANoptosis and its role in T cell-based immunotherapy View all articles

Nanomaterials: Leading Immunogenic Cell Death-based Cancer Therapies

Provisionally accepted
Changyu Ma Changyu Ma 1,2*Zhe Cheng Zhe Cheng 3*Haotian Tan Haotian Tan 1,2*Yihan Wang Yihan Wang 2,4*Shuzhan Sun Shuzhan Sun 1,2*Mingxiao Zhang Mingxiao Zhang 2*Jianfeng Wang Jianfeng Wang 2*
  • 1 Peking Union Medical College Graduate School, Beijing, China
  • 2 Department of Urology, China-Japan Friendship Hospital, Beijing, China
  • 3 Department of Forensic Medicine, Harbin Medical University, Harbin, Heilongjiang, China
  • 4 Health Science Centre, Peking University, Beijing, Beijing Municipality, China

The final, formatted version of the article will be published soon.

    The field of oncology has transformed in recent years, with treatments shifting from traditional surgical resection and radiation therapy to more diverse and customized approaches, one of which is immunotherapy. ICD (immunogenic cell death) belongs to a class of regulatory cell death modalities that reactivate the immune response by facilitating the interaction between apoptotic cells and immune cells and releasing specific signaling molecules, and DAMPs (damage-associated molecular patterns).The inducers of ICD can elevate the expression of specific proteins to optimize the TME (tumor microenvironment). The use of nanotechnology has shown its unique potential. Nanomaterials, due to their tunability, targeting, and biocompatibility, have become powerful tools for drug delivery, immunomodulators, etc., and have shown significant efficacy in clinical trials. In particular, these nanomaterials can effectively activate the ICD, trigger a potent anti-tumor immune response, and maintain long-term tumor suppression. Different types of nanomaterials, such as biological cell membrane-modified nanoparticles, self-assembled nanostructures, metallic nanoparticles, mesoporous materials, and hydrogels, play their respective roles in ICD induction due to their unique structures and mechanisms of action.Therefore, this review will explore the latest advances in the application of these common nanomaterials in tumor ICD induction and discuss how they can provide new strategies and tools for cancer therapy. By gaining a deeper understanding of the mechanism of action of these nanomaterials, researchers can develop more precise and effective therapeutic approaches to improve the prognosis and quality of life of cancer patients. Moreover, these strategies hold the promise to overcome resistance to conventional therapies, minimize side effects, and lead to more personalized treatment regimens, ultimately benefiting cancer treatment.

    Keywords: ICD, nanomaterials, DAMPs, TME, immune therapy

    Received: 12 Jun 2024; Accepted: 24 Jul 2024.

    Copyright: © 2024 Ma, Cheng, Tan, Wang, Sun, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Changyu Ma, Peking Union Medical College Graduate School, Beijing, 100730, China
    Zhe Cheng, Department of Forensic Medicine, Harbin Medical University, Harbin, 130012, Heilongjiang, China
    Haotian Tan, Department of Urology, China-Japan Friendship Hospital, Beijing, China
    Yihan Wang, Health Science Centre, Peking University, Beijing, 100191, Beijing Municipality, China
    Shuzhan Sun, Department of Urology, China-Japan Friendship Hospital, Beijing, China
    Mingxiao Zhang, Department of Urology, China-Japan Friendship Hospital, Beijing, China
    Jianfeng Wang, Department of Urology, China-Japan Friendship Hospital, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.